Clinical Research Directory
Browse clinical research sites, groups, and studies.
Back to Studies
NOT YET RECRUITING
NCT07524920
PHASE2
Comparing Efficacy and Safety of (Meropenem + Colistin) Versus (Imipenem/Cilastatin + Tigecycline) on Eradication of Multi-Drug Resistance Bacteria
Sponsor: Ain Shams University
View on ClinicalTrials.gov
Summary
This study aims to compare the efficacy and safety of two antibiotic combinations (Colistin + Meropenem) vs (Imipenem/cilastatin+ Tigecycline) in the treatment of adults with MDR gram-negative infections.
Key Details
Gender
All
Age Range
18 Years - 85 Years
Study Type
INTERVENTIONAL
Enrollment
60
Start Date
2026-04-01
Completion Date
2026-09-01
Last Updated
2026-04-13
Healthy Volunteers
No
Conditions
Interventions
DRUG
"Imipenem/cilastatin" and "Tigecycline"
Imipenem/cilastatinis 500mg or 1gm every 6 to 8 hrs , Tigecycline 200 mg loading dose once followed by 100mg BID
DRUG
"colistin" and "meropenem"
meropenem IV 2g TID , colistin IV 9M loading then 5M BID
Locations (1)
El-Demerdash hospital
Cairo, Egypt